Literature DB >> 10682234

Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.

M Sunami1, T Nishikawa, A Yorogi, M Shimoda.   

Abstract

A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly. His akathisia symptoms worsened thereafter. Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia. Two days' administration of levomepromazine 100 mg led him to a coma for 2 days. Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically. He became completely premorbid 2 weeks after administration of levodopa. The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682234     DOI: 10.1097/00002826-200001000-00012

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

1.  Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin.

Authors:  Ahmed Yacoob Mayet
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

2.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

3.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

4.  Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Authors:  Jennifer C Felger; Li Li; Paul J Marvar; Bobbi J Woolwine; David G Harrison; Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2012-10-13       Impact factor: 7.217

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 6.  The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-01-20       Impact factor: 5.590

7.  Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.

Authors:  Marcia D McNutt; Shuling Liu; Amita Manatunga; Erica B Royster; Charles L Raison; Bobbi J Woolwine; Marina F Demetrashvili; Andrew H Miller; Dominique L Musselman
Journal:  Neuropsychopharmacology       Date:  2012-02-22       Impact factor: 7.853

Review 8.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.

Authors:  Matthias Majer; Leonie A M Welberg; Lucile Capuron; Giuseppe Pagnoni; Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-02-06       Impact factor: 7.217

Review 10.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.